Viewing Eye Care Network

AMD

Latest News


CME Content


The study, co-led by Griffith University’s Menzies Health Institute and South Korea’s Center for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technology, aims to understand how SARS-CoV-2 affects the eyes and whether it could serve as a virus infection route.

Scientists from the Clear Vision Research Lab at The Australian National University and the Korean biotech company MDimune Inc. hope to turn recent research milestones into potential treatments for AMD.

Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.

Timing is everything with early treatment of AMD

In a real-world setting, eyes with AMD with a relatively good initial best-corrected visual acuity and no fibrovascular pigment epithelial detachment sustained or improved BCVA after anti-VEGF therapy within 3 years of follow-up.

Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.